Longfellow Investment Management Co. LLC Takes Position in Abbott Laboratories $ABT

Longfellow Investment Management Co. LLC purchased a new position in shares of Abbott Laboratories (NYSE:ABT) in the 3rd quarter, Holdings Channel reports. The institutional investor purchased 6,053 shares of the healthcare product maker’s stock, valued at approximately $811,000.

Other institutional investors also recently added to or reduced their stakes in the company. Charles Schwab Trust Co lifted its stake in shares of Abbott Laboratories by 109.8% in the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after purchasing an additional 15,394 shares during the period. Asset Management One Co. Ltd. increased its holdings in Abbott Laboratories by 2.4% in the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after buying an additional 19,966 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after acquiring an additional 18,974 shares during the period. AE Wealth Management LLC boosted its stake in shares of Abbott Laboratories by 20.8% during the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after acquiring an additional 11,264 shares in the last quarter. Finally, Mawer Investment Management Ltd. grew its holdings in shares of Abbott Laboratories by 5.9% in the 3rd quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker’s stock worth $168,199,000 after acquiring an additional 70,122 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Barclays reduced their price objective on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Daiwa Securities Group lowered their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Royal Bank Of Canada cut their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Piper Sandler dropped their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Insider Transactions at Abbott Laboratories

In related news, EVP Mary K. Moreland sold 613 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $110.97 on Friday. The stock has a market capitalization of $192.83 billion, a P/E ratio of 29.83, a P/E/G ratio of 1.80 and a beta of 0.74. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $139.15. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm’s 50-day moving average is $116.39 and its two-hundred day moving average is $124.82.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the previous year, the business posted $1.34 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is currently 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.